Cell and Gene Therapy Catapult joins Innovate UK-funded consortium to develop AI-driven "lab of the future" for cell therapy development

London, United Kingdom, 19 November 2026: Cell and Gene Therapy Catapult (CGT Catapult) has been awarded funding as part of a consortium led by Danu Insights, alongside MFX Bio and Lift Therapeutics, under Innovate UK’s Medicines Manufacturing: Labs of the Future programme. The project, ADAPT (AI-Driven Adaptive Process Technology), will develop an automated platform designed to make cell therapy development faster, cheaper and more reproducible.

The consortium has been awarded grant funding of £1.4 million towards a total project of £1.8 million.

Cell therapies derived from induced pluripotent stem cells (iPSCs) hold enormous promise for treating conditions including cancer, liver disease and diabetes. However, developing suitable manufacturing processes remains slow, costly and labour-intensive. Today, scientists typically refine processes through manual, one-at-a-time experiments, with only occasional checks of the cell culture environment, and no systematic way to respond when conditions change. As a result, important changes can go undetected, making successful outcomes difficult to replicate and delaying the impact for patients.

ADAPT will bring together two UK-developed technologies to change this. Danu Insights’ AI platform builds rich models of the underlying biology, combining existing scientific knowledge with machine learning to capture what is known and estimate what is not. It then uses these models to choose each experiment for what it will reveal, not just what it will achieve, making the most of every run. This works in tandem with MFX Bio’s automated bioreactor system, which can run up to nine experiments in parallel while continuously monitoring conditions such as pH, oxygen and nutrient levels in real time. By connecting the two, the platform creates a closed loop: real-time data from the bioreactors continuously refines the models, which in turn guide the best actions to take, both during a run and between runs, allowing the laboratory to operate intelligently around the clock with human oversight.

This approach has the potential to dramatically reduce the number of experiments needed to optimise a process, speeding up development timelines from months to weeks while generating richer, more standardised data to support regulatory success. Lift Therapeutics will act as the project’s end-user partner, providing a real-world test case for the platform. Lift Therapeutics is developing Immuno-Modulatory Alpha Neutrophils (IMANs)®, a first-in-class neutrophil immunotherapy for solid tumours; by incorporating ADAPT into its process development, it aims to reduce the time and cost of developing an iPSC-derived IMAN and support wider adoption across markets.

CGT Catapult's role

As the consortium’s research and technology partner, CGT Catapult will contribute its expertise in multi-parametric bioprocessing and process control, along with its specialist facilities, lead the work to establish the platform benchmarks, and validate that improvements achieved at small scale can be maintained during scale-up. CGT Catapult will also lead workforce training and dissemination, developing the materials needed to help the consortium and scientists across the sector adopt these new AI-assisted ways of working, and providing project management support across the team.

By directly addressing cell therapy process development, this project is helping to tackle one of the sector’s most significant challenges: reducing production costs and helping to bring these transformative treatments to patients more affordably and quickly.

ADAPT builds on an existing relationship between CGT Catapult and Danu Insights. CGT Catapult was involved in Innovate UK’s Agentic AI Pioneers Prize, helping to guide applicants in shaping their solutions to address challenges in health and life sciences. Danu Insights went on to win both the Health and Life Sciences category and the overall prize, recognised for its digital-twin approach to cell and gene therapy development. ADAPT deepens that relationship, applying Danu’s technology to a real advanced therapy manufacturing challenge.

What happens if we work out a cure for cancer, but cannot produce it at a price that anyone can afford? That is essentially what is beginning to happen with a lot of cell therapies, and exactly what ADAPT is aiming to fix. Our AI learns from live data coming off the manufacturing hardware, and suggests the best possible experiment to improve the process.

Dr Stefan Bostock, CEO and Co-Founder of Danu Insights

This project aims to demonstrate the versatility of MFX’s instrument for process development across yet another cell type: induced pluripotent stem cells (iPSCs). I’m excited to bring together Danu’s data analysis, Catapult’s process development expertise and LIfT’s innovative programme with MFX’s lab-in-box.

Antoine Espinet, CEO of MFX Bio

The potential of cell and gene therapies will only be fully realised if we can develop and manufacture them more efficiently and affordably. This project brings together automation, real-time data and artificial intelligence to transform how cell therapy processes are developed, replacing slow, manual trial-and-error with a faster, smarter, AI-guided approach. We are delighted to be working alongside Danu Insights, MFX Bio and LIfT Therapeutics, building on our earlier support for Danu through the Agentic AI Pioneers Prize, to help strengthen the UK's position at the forefront of advanced therapy manufacturing.

Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult